EBOS Group (EBO) Fair Value & Analysis
Healthcare · AU · Market cap A$3.4B
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 5 days ago
Fair value updated Jun 24, 2026 — revised from A$28.26 to A$24.86 (−12.0%) since Jun 23, 2026. Share price +3.1% over the past month.
Price vs Fair Value (12 months)
12‑month range A$15.79 – A$36.41 · fair‑value band A$18.64 – A$31.07 · the A$16.72 price screens below the A$24.86 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
EBOS Group (EBO) currently trades at A$16.72, while our model-based Fair Value estimate is A$24.86 — implying the stock looks roughly 48.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, EBOS Group generated revenue of A$13.0B at a net margin of 1.8%. Revenue grew 13.0% year over year. It earns a return on equity of 9.0%. Net debt stands at A$1.5B. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand. It operates through Healthcare and Animal Care segments. The company provides healthcare logistics; medication management solutions; pharmacy management software; loyalty, generics, compliance, business intelligence, and store software services; and health communications, programs, and consultancy services. It also offers community based health care services and programs; vitamins, minerals and supplements, herbal and fruit teas, and natural toothpastes, as well as functional foods, including molasses and manuka honey; Pharmacy Choice, a five step integrated retail program for independent pharmacies; and healthSAVE, a community pharmacy banner that helps members drive their retail businesses. Further, it offers healthcare distribution, warehousing, clinical trial management, and product registration s…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
EBOS Group reported revenue of A$13.2B in FY2025 versus A$9.9B in FY2021, a compound +7.5%/yr. Reported net income was A$232M in FY2025, compounding +3.9%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation M1CK34 | R$999.49 | R$1,236 | +24% |
| Cencora, Inc C1CO34 | R$707.04 | R$79.88 | -89% |
| Cardinal Health, Inc CAH | $201.74 | $92.07 | -54% |
| Sigma Healthcare Limited SIGGF | $2.35 | $0.7800 | -67% |
| Sitka Gold Corp SIG | A$2.76 | A$0.3300 | -88% |
| Shanghai Pharmaceuticals Holding 601607 | ¥15.96 | ¥56.73 | +255% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is EBOS Group (EBO) undervalued?
What is the fair value of EBO?
What is the quality score of EBO?
What is the revenue of EBOS Group (EBO)?
What is the net profit margin of EBO?
Does EBOS Group pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.